How is hydralazine used, including its indications, dosing regimens, contraindications, and monitoring recommendations for hypertension and heart failure?

Hydralazine: Clinical Use in Hypertension and Heart Failure

Primary Indications

Hydralazine is NOT a first-line agent for routine hypertension or heart failure management. Its use is reserved for specific clinical scenarios where standard therapies cannot be used or as adjunctive therapy in select populations.

Heart Failure with Reduced Ejection Fraction (HFrEF)

The combination of hydralazine plus isosorbide dinitrate (Hy+ISDN) is specifically indicated for:

• Self-identified African American patients with NYHA Class III-IV HFrEF who remain symptomatic despite optimal therapy with ACE inhibitors (or ARBs), beta-blockers, and mineralocorticoid receptor antagonists 1, 2
• Patients intolerant to ACE inhibitors AND ARBs due to hypotension, renal insufficiency, or drug intolerance (though referral to a heart failure specialist is recommended) 3, 1, 2

The evidence supporting Hy+ISDN in African Americans is robust, showing mortality reduction and improved exercise capacity 1. However, hydralazine should NOT be used alone without a nitrate in heart failure 4.

Hypertensive Emergencies

Hydralazine is NOT a preferred first-line agent for hypertensive emergencies due to its unpredictable response and prolonged duration of action 5, 6, 7.

IV Hydralazine dosing for hypertensive emergencies:

• Initial: 10 mg slow IV infusion (maximum initial dose 20 mg)
• Repeat every 4-6 hours as needed
• Onset: 10-30 minutes; Duration: 2-4 hours 5, 6

Critical limitations: The unpredictability of BP response and inability to titrate make nicardipine, clevidipine, or labetalol preferable options 5.

Hypertension in Pregnancy

Hydralazine is a first-line agent for acute hypertension in pregnancy:

• 5 mg IV or IM, then 5-10 mg every 20-40 minutes (maximum cumulative dose 20 mg)
• Alternative: constant infusion 0.5-10 mg/hour
• Onset: 10-20 minutes 8

Important caveat: Higher or frequent dosing is associated with maternal hypotension, headaches, and abnormal fetal heart rate tracings 8.

Resistant Hypertension in HFrEF

For hypertensive patients with HFrEF whose BP remains uncontrolled despite ACE inhibitor/ARB, beta-blocker, MRA, and diuretics:

• Hydralazine (with or without ISDN) is recommended as step 3 therapy 9
• Amlodipine or felodipine are alternatives 9

Dosing Regimens

Oral Hydralazine (Chronic Use)

• Starting dose: 10-25 mg twice daily
• Maintenance: 50-100 mg twice daily (in combination with ISDN for heart failure)
• Maximum: 200 mg twice daily (though doses of 150-3000 mg/24h have been reported) 10
• Frequency: Twice daily dosing is necessary; once-daily conventional formulations are inadequate 11

Pharmacokinetics

• Absorption: Rapid, peak levels at 1-2 hours
• Half-life: 3-7 hours
• Metabolism: Extensive hepatic metabolism via polymorphic acetylation
• Acetylator status: Slow acetylators have higher plasma levels and require lower doses; rapid acetylators may need higher doses 12, 10

Contraindications and Precautions

Absolute Contraindications

• Coronary artery disease (relative—may precipitate angina due to reflex tachycardia)
• Mitral valve rheumatic heart disease

Use with Extreme Caution

• Avoid in left ventricular hypertrophy as a primary agent 13
• Not recommended for routine inpatient management of asymptomatic hypertension—frequently causes hypotension and adverse events 14, 15, 16

Drug Interactions

• Do NOT combine hydralazine alone with ACE inhibitors/ARBs in heart failure—must use with isosorbide dinitrate 4, 2
• Insufficient data for concomitant use of Hy+ISDN with ARNi (sacubitril/valsartan) 2

Monitoring Recommendations

Before Initiation

• Baseline blood pressure (standing and supine)
• Heart rate
• Renal function
• Complete blood count (risk of drug-induced lupus with chronic use)

During Therapy

• Blood pressure: Monitor closely for hypotension, especially in hospitalized patients receiving IV doses 14, 15
• Heart rate: Expect reflex tachycardia (4-13 bpm increase) 14
• Renal function: Particularly when used with ACE inhibitors/ARBs
• Drug-induced lupus syndrome: Monitor for arthralgias, fever, rash (more common with doses >200 mg/day and slow acetylators)

Adverse Events

• Most common: Hypotension (especially with IV use), headache, tachycardia, fluid retention
• Serious: Drug-induced lupus, peripheral neuropathy (with chronic high-dose use)

Common Pitfalls to Avoid

1. Using IV hydralazine for asymptomatic hypertension in hospitalized patients: This is the most common misuse—69% of IV hydralazine use lacks appropriate indication 15. It causes unpredictable BP drops and hypotension without improving outcomes 14, 16.

2. Using hydralazine alone in heart failure: Always combine with isosorbide dinitrate; hydralazine monotherapy showed no mortality benefit 4, 2.

3. Prescribing as first-line for hypertensive emergencies: Prefer titratable agents like nicardipine or clevidipine 5, 6.

4. Failing to continue home antihypertensives: 40.8% of patients receiving PRN hydralazine had their home medications discontinued—this is inappropriate practice 16.

5. Not intensifying outpatient regimens: Using PRN hydralazine as a substitute for optimizing chronic antihypertensive therapy is poor practice 16.

Clinical Algorithm for Use

Step 1: Determine if patient has a guideline-supported indication:

• African American with symptomatic HFrEF on maximal therapy → Hy+ISDN
• ACE inhibitor/ARB intolerance in HFrEF → Consider Hy+ISDN (after specialist consultation)
• Acute hypertension in pregnancy → IV hydralazine
• Resistant hypertension in HFrEF → Hydralazine (step 3 agent)

Step 2: If no clear indication exists, DO NOT USE hydralazine—choose alternative agents.

Step 3: If using for heart failure, always combine with isosorbide dinitrate unless treating acute hypertension in pregnancy.

Step 4: Monitor closely for hypotension, reflex tachycardia, and fluid retention.